The Latest Breaking News from LLY

Eli Lilly shares have underperformed the broader market over the past year, but Wall Street analysts remain firmly bullish in the company’s long-term growth prospects.

Eli Lilly and Co. (NYSE:LLY) released topline results from SURPASS-CVOT, a head-to-head Phase 3 cardiovascular outcomes trial comparing Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, to Trulicity (dulaglutide), a GLP-1 receptor agonist.

On July 8, US President Donald Trump shook the biopharmaceutical sector by announcing a tariff of up to 200% on pharmaceuticals, which would take effect “very soon.” 80% of prescription drugs sold in the US are made abroad, a statistic the President wants to flip on its head.

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion on Friday recommending Eli Lilly and Co.’s (NYSE:LLY) donanemab for early symptomatic Alzheimer’s disease in adults with confirmed amyloid pathology who are apolipoprotein E ε4 (ApoE4) heterozygotes or non-carriers.

Eli Lilly is expected to release its fiscal second-quarter earnings next month, and analysts project a double-digit profit growth.

GLP-1 medications are delivering a $6.5 billion blow to U.S. grocery spending, with weight-loss drugs fundamentally altering consumer food purchasing patterns across America’s retail landscape.

While President Donald Trump's proposed 200% tariffs on pharmaceutical imports could potentially squeeze the profit margins, this stock is poised to “benefit” from the levies.

These 3 blue-chip stocks offer strong earnings power and growth opportunities as uncertainty lingers in the second half of 2025

While multinational pharmaceutical firm Eli Lilly and Company (NYSE:LLY) represents one of the top drugmakers in the world, that status alone hasn't exempted its equity from underperformance. In the past 52 weeks, LLY stock finds itself down almost 16%. Since the beginning of this year, LLY has barely poked its…